JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200 million (USD 28 million) in a Series B+ financing round. This follows a Series B funding of RMB 100 million (USD 14 million) in May, bringing the total funds raised to RMB 350 million (USD 49 million). The latest round was led by SDIC Unity Capital, with participation from Ariose Capital, Oriza Holdings, and So-Young. The funds will be utilized to accelerate pipeline development, expand into the fields of serious and consumer medical sectors, and advance the industrial implementation and commercial promotion of the product pipeline.
Established in 2020, JHM Biopharma has developed an innovative recombinant protein drug development platform that includes a high-efficiency expression system for recombinant proteins, a unique micro-denaturation separation and purification technology, an in vitro protein folding and self-assembly system, and a long-term sustained release mechanism. The company’s pipeline is primarily focused on metabolic diseases and medical aesthetics. – Flcube.com
